AstraZeneca today announced that it has entered into a settlement agreement in its US patent infringement litigation against Watson Laboratories, Inc., Actavis, Inc. (formerly known as Watson Pharmaceuticals, Inc.), and EGIS Pharmaceuticals regarding Watson's proposed rosuvastatin zinc product.

New data presented at the 65th annual meeting of the American Academy of Neurology (AAN) show Gilenya® (fingolimod), the first oral disease modifying therapy approved to treat relapsing forms of multiple sclerosis (MS), significantly and consistently reduced the rate of brain volume loss.

Amgen (NASDAQ:AMGN) announced top-line results from the Phase 3 trial in melanoma, which evaluated the efficacy and safety of talimogene laherparepvec for the treatment of unresected stage IIIB, IIIC or IV melanoma compared to treatment with subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF).

The Children's Hospital of Philadelphia is proud to announce a $500,000 gift from the GlaxoSmithKline (GSK) Foundation. The donation will greatly enhance the GlaxoSmithKline Hope for Families Fund, an endowment fund which was established in 2008 with a $1 million gift from The GlaxoSmithKline Foundation and GlaxoSmithKline, and matched by The Children's Hospital of Philadelphia.

AstraZeneca has announced plans to invest in strategic research and development centres in the UK, the US and Sweden to improve pipeline productivity and to establish the company as a global leader in biopharmaceutical innovation.

Merck today announced a strategic alliance with Nordic Bioscience Clinical Development A/S on Merck's investigational drug sprifermin (recombinant human FGF-18) in osteoarthritis (OA) of the knee. This agreement underscores Merck's commitment to osteoarthritis research and development.

Shire plc (LSE: SHP, NASDAQ: SHPG) has acquired Premacure AB of Uppsala, Sweden, a privately held biotechnology company developing a protein replacement therapy, currently in Phase II development, for the prevention of retinopathy of prematurity (ROP). ROP is a rare and potentially blinding eye disorder that primarily affects premature infants and is one of the most common causes of visual loss in childhood.